Diagnostics are a top-three revenue line in general practice and, done wrong, a top-three source of dead capital. The startup question isn’t really “which analyzer?” — it’s which testing lives in-house versus at the reference lab, and how to acquire the in-house piece without spending $18,000+ of opening capital. The market has largely answered both.
The split every practice runs
Most practices use both: in-house analyzers when results guide treatment now — the sick patient, the pre-anesthetic panel — and a reference lab for routine and complex work. The logic is stable because each side is better at its job: reference labs run higher-end equipment producing more analytes, more checks, and more abnormality flags than in-clinic units can, plus pathologist review — while in-house wins on the only dimension that matters mid-appointment: minutes instead of tomorrow. Day-one in-house core for a GP: chemistry, hematology (CBC), electrolytes, urinalysis support, and snap-test reading — enough to work up the vomiting dog and clear the anesthesia candidate. Send out: histopathology, cultures, endocrine panels beyond the basics, cytology review, and routine wellness bloodwork where overnight turnaround is fine.
How to acquire it: almost never a purchase
Bought outright, a chemistry + hematology setup runs ~$18,000+ — but the dominant acquisition model has shifted the capital question entirely. Diagnostics companies place analyzers under reagent-rental / consumables agreements: no capital investment or lease required, no analyzer maintenance fees — the machine is effectively provided, and you commit to buying the tests. You pay per test (or via monthly consumable minimums); maintenance, calibration, software updates, and often loaner replacement ride along. For a startup this is nearly always right: zero capital, full capability on day one, vendor-carried obsolescence risk. The trade-offs to negotiate with eyes open:
- Volume commitments. Minimums sized for a mature practice can sting during the ramp — negotiate a startup ramp schedule into the agreement (vendors compete for new practices; ask).
- Term and exit. These agreements bind you to a diagnostics ecosystem for years. Understand the term, the out, and what happens to per-test pricing at renewal.
- The ecosystem effect. IDEXX leads the market by a wide margin, with Zoetis and Mars-affiliated labs as the main alternatives — and your in-house vendor will bundle reference-lab pricing, snap tests, and software integration. Price the bundle across vendors, not the analyzer. Smaller regional labs also exist and compete on price and service for the send-out side.
The economics to actually check
In-house testing margins are real — in-house machines can let the practice keep a higher share of each test’s profit, volume and contract terms permitting — but only if utilization holds. Before signing, model it: projected in-house tests/day × your fee (see the fee guide) versus the consumable cost and minimums. A one-doctor startup typically clears the bar comfortably on pre-anesthetic panels and sick-patient chemistries alone; if your model needs wellness screening volume you don’t have yet, negotiate the ramp rather than buying hope. Two operational notes that protect the margin: PIMS integration (results flowing into the record automatically — charge capture leaks when results are paper), and fee discipline — in-house tests are shopped less than exams; price them to their value (immediacy) rather than to reference-lab parity.
Decision summary
| Reagent rental | Purchase | Reference lab only | |
| Opening capital | \~\$0 | \$18K+ | \$0 |
| Maintenance risk | Vendor's | Yours | — |
| Per-test cost | Higher | Lower at volume | Highest margin loss on stat work |
| Right for | Nearly all startups | High-volume, data-driven year-3+ practices | Practices without stat needs (rare) |